Solomon Graf

Dr. Solomon Graf


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2019 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
GIGeorge N. Ioannou
George N. Ioannou
PGPamela K. Green
Pamela K. Green
KBKristin Berry
Kristin Berry
SGSolomon Graf
Solomon Graf
It is unclear whether eradication of hepatitis C virus (HCV) leads to a reduction in the risk of hematologic malignancies. We aimed to determine the impact of sustained virologic response (SVR) induced by either direct‐acting antivirals (DAAs) or interferon (IFN) on the risk of hematologic malignancies. We identified 69,581 patients who initiated antiviral treatment in the Veterans Affairs national health care system from January 1, 1999, to December 31, 2015, including 40,410 (58%) IFN‐only regimens, 4,546 (6.5%) DAA + IFN regimens, and 24,625 (35%) DAA‐only regimens. We retrospectively followed patients to identify incident cases of hematologic malignancies or monoclonal gammopathy of unknown significance (MGUS), a premalignant precursor of multiple myeloma. Among patients treated with IFN, SVR was significantly associated with a reduction in the risk of lymphoma (adjusted hazard ratio [AHR], 0.70; 95% confidence interval [CI], 0.51‐0.97), multiple myeloma (AHR, 0.40; 95% CI, 0.20‐0.77), MGUS (AHR, 0.65; 95% CI, 0.42‐0.99), or all hematologic malignancies and MGUS combined (AHR, 0.67; 95% CI, 0.53‐0.84) over a mean follow‐up of 10.6 years. In contrast, among patients treated with DAA, SVR was not associated with the risk of lymphoma, multiple myeloma, MGUS, or all hematologic malignancies and MGUS combined (AHR, 1.08; 95% CI, 0.66‐1.78) during a mean follow‐up of 2.9 years. Neither IFN‐induced SVR nor DAA‐induced SVR was associated with risk of colon cancer or prostate cancer, which were chosen a priori as comparison/control malignancies. Conclusion: We describe novel strong associations between IFN‐induced SVR and lymphoma, multiple myeloma, MGUS, and all hematologic malignancies combined. Surprisingly, these associations were not observed with DAA‐induced SVR.

10 October 2020 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
HKHeather Klocke
Heather Klocke
ZDZhao Ming Dong
Zhao Ming Dong
COCraig O’brien
Craig O’brien
NBNicholas Burwick
Nicholas Burwick
RRRobert E. Richard
Robert E. Richard
SGSolomon Graf
Solomon Graf
T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS) is an uncommon and aggressive leukemia without well-established treatment guidelines, particularly when relapsed. Venetoclax plus a hypomethylating agent offers a promising option in this situation since studies support its use in both acute myeloid and, albeit with fewer data to date, acute T-cell-lymphoblastic leukemias. We report the successful eradication of T/myeloid MPAL NOS relapsed after allogeneic stem cell transplant with venetoclax plus decitabine. A consolidative allogeneic stem cell transplant from a second donor was subsequently performed, and the patient remained without evidence of disease more than one year later. Further investigation is indicated to evaluate venetoclax combined with hypomethylating agents and/or other therapies for the management of T/myeloid MPAL NOS.

1 March 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
SGSolomon Graf
Solomon Graf
RCRyan D. Cassaday
Ryan D. Cassaday
KMKarolyn Morris
Karolyn Morris
JVJenna M. Voutsinas
Jenna M. Voutsinas
QWQian Vicky Wu
Qian Vicky Wu
AGAjay K. Gopal
Ajay K. Gopal

1 January 2005 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Open access
PDF file
GTGilad Twig
Gilad Twig
SGSolomon Graf
Solomon Graf
MMMark A. Messerli
Mark A. Messerli
PSPeter J. S. Smith
Peter J. S. Smith
SYSeung H. Yoo
Seung H. Yoo
OSOrian Shirihai
Orian Shirihai
Activation of the microglial neurotoxic response by components of the senile plaque plays a critical role in the pathophysiology of Alzheimer's disease (AD). Microglia induce neurodegeneration primarily by secreting nitric oxide (NO), tumor necrosis factor-α (TNFα), and hydrogen peroxide. Central to the activation of microglia is the membrane receptor CD40, which is the target of costimulators such as interferon-γ (IFNγ). Chromogranin A (CGA) is a recently identified endogenous component of the neurodegenerative plaques of AD and Parkinson's disease. CGA stimulates microglial secretion of NO and TNFα, resulting in both neuronal and microglial apoptosis. Using electrochemical recording from primary rat microglial cells in culture, we have shown in the present study that CGA alone induces a fast-initiating oxidative burst in microglia. We compared the potency of CGA with that of β-amyloid (βΑ) under identical conditions and found that CGA induces 5–7 times greater NO and TNFα secretion. Coapplication of CGA with βΑ or with IFNγ resulted in a synergistic effect on NO and TNFα secretion. CD40 expression was induced by CGA and was further increased when βΑ or IFNγ was added in combination. Tyrphostin A1 (TyrA1), which inhibits the CD40 cascade, exerted a dose-dependent inhibition of the CGA effect alone and in combination with IFNγ and βΑ. Furthermore, CGA-induced mitochondrial depolarization, which precedes microglial apoptosis, was fully blocked in the presence of TyrA1. Our results demonstrate the involvement of CGA with other components of the senile plaque and raise the possibility that a narrowly acting agent such as TyrA1 attenuates plaque formation.

24 February 2022 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
JSJanelle Schweitzer
Janelle Schweitzer
MHMeghan Hoffman
Meghan Hoffman
SGSolomon Graf
Solomon Graf
Between 2014 and 2018 The United States Food and Drug Administration granted approvals for three small molecule inhibitors of phosphoinositide 3-kinases (PI3Ks) as monotherapy for follicular lympho...

1 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
SGSolomon Graf
Solomon Graf
RLRyan C. Lynch
Ryan C. Lynch
CUChaitra S. Ujjani
Chaitra S. Ujjani
TGTed A. Gooley
Ted A. Gooley
HRHeather Rasmussen
Heather Rasmussen
AGAjay K. Gopal
Ajay K. Gopal
Patients with indolent B-cell non-Hodgkin lymphoma (iNHL) generally require treatment but experience normal survival, emphasizing the need for simpler, safer therapies. Proteasome inhibitors target aberrant signaling pathways within iNHL and have manageable toxicities. We evaluated the oral proteasome inhibitor ixazomib as initial monotherapy, and combined with rituximab, for first-line treatment of iNHL. Treatment-naïve patients with iNHL needing therapy received oral ixazomib 4 mg weekly until progressive disease or unacceptable adverse events. A 4-week course of rituximab was added during month 7. The primary end point was overall response rate (ORR) during the ixazomib monotherapy window. Correlations included gene expression profiling and response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Thirty-three patients with follicular lymphoma (FL) (n = 20), marginal zone lymphoma (n = 7), and other iNHL were treated with a median follow-up of 30.3 months. During the 6-month ixazomib window, the ORR was 24%, including 35% in FL. The best ORR over the entire study period was 52% overall and 65% in FL; complete response was achieved in 33% and 45%, respectively. The median duration of response was 25.8 months (range, 0-49.7), and the 24-month progression-free and overall survival rates were 51% (95% confidence interval [CI], 32-67) and 91% (95% CI, 74-97), respectively. Ixazomib was well tolerated. Baseline downregulation of proteasome genes, PSMB9 (P = .03) and PSMB8 (P = .007), were associated with response. All evaluated patients generated anti-S antibodies to SARS-CoV-2 vaccination, with a median of 254.9 binding arbitrary unit per mL. Ixazomib demonstrated efficacy alone and with short-course rituximab in untreated iNHL while exhibiting favorable toxicity, convenience, and retention of the B-cell immune response. This trial is registered at www.clinicaltrials.gov as NCT02339922.